What is Hefei Lifeon Pharmaceutical Co., Ltd.'s (003020.SZ) StockRank?

MoatMap's StockRank for Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) is 45/100, with a Hold signal. This is a composite score combining Quality (69), Value (43), and Momentum (25) factor ranks across MoatMap's 19,000+ stock universe.

Does Hefei Lifeon Pharmaceutical Co., Ltd. have an economic moat?

Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) has a Quality factor score of 69/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Hefei Lifeon Pharmaceutical Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) is Hold, based on a StockRank of 45/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Hefei Lifeon Pharmaceutical Co., Ltd. in?

Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

003020.SZ

HOLDREMOVE

Hefei Lifeon Pharmaceutical Co., Ltd. · Healthcare · China · $557M · Avg Vol: $5M/d

StockRank

P/E (TTM)

21.3x

ROE

8.1%

D/E

0.0x

Dividend %

2.7%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

A domestic-focused pharmaceutical firm that lacks the global scale, regulatory moats, or CDMO capabilities to benefit from the high-conviction healthcare themes.

COMPANY DESCRIPTION

Hefei Lifeon Pharmaceutical Co., Ltd. researches, develops, manufactures, and markets pharmaceutical products, focusing on cardiovascular, orthopedic, and pediatric therapeutic areas. The company possesses a robust portfolio of proprietary Chinese patent medicines and generic chemical drugs, supported by a nationwide clinical sales network. Its continuous investment in R&D and bio-equivalence testing ensures a steady pipeline of high-margin products.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	381M	281M	224M	230M	-15.5%
EPS	0.16	0.17	0.12	0.13	-7.8%
Shares	191M	192M	192M	190M	-0.5%
Debt	2M	6M	10M	9M	68.3%
Equity	219M	249M	257M	267M	6.9%
Op CF	30M	30M	29M	31M	2.0%
Inv CF	-30M	-47M	-27M	-9M	—
Fin CF	-7M	5M	-12M	-27M	—

PRICE (1M)-32.2%

SMA 50SMA 200

$2.28

RSI (14)

33.1

52W High

$4.98

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

8.9%70.1

ROE

8.1%66.2

GP/Assets

38.8%77.8

Op. Margin

11.6%69.2

FCF/Assets

1.6%55.9

Piotroski

—83.5

Int. Cover

50.0x91.4

D/E Ratio

0.04x76.7

Current Ratio

2.28x42.6

Value

P/E (TTM)

21.3x53.7

EV/EBITDA

15.0x27.8

P/FCF

638.1x12.4

P/B

1.9x57.4

P/S

2.3x64.4

Div Yield

2.7%62.8

Momentum

52W High %

46%19.0

RS 6M

-40%29.2

SMA 50/200

0.83x18.0

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

-8%33.7

FUNDAMENTALS

Market Cap

$557M

P/E (Forward)

—

Gross Margin

64.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 003020.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
003020.SZ	Hefei Lifeon Pharmaceutical Co., Ltd.(you)	$557M	45	HOLD
002880.SZ	Shenzhen Weiguang Biological Products Co., Ltd.	$845M	48	HOLD
1477.HK	Ocumension Therapeutics	$636M	37	HOLD
301333.SZ	R&G PharmaStudies Co., Ltd.	$724M	38	HOLD
688293.SS	Shanghai OPM Biosciences Co., Ltd.	$898M	42	HOLD
1873.HK	Viva Biotech Holdings	$337M	41	HOLD
688767.SS	Hangzhou Biotest Biotech Co.,Ltd.	$842M	39	HOLD
688399.SS	Jiangsu Bioperfectus Technologies Co., Ltd.	$658M	34	SELL
600866.SS	Star Lake Bioscience Co., Inc.Zhaoqing Guangdong	$1.2B	46	HOLD
603229.SS	Zhejiang Ausun Pharmaceutical Co., Ltd.	$1.2B	43	HOLD

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) — Stock Score Summary

Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) has a MoatMap StockRank of 45/100 based on Quality (69/100), Value (43/100), and Momentum (25/100) factor scores. The current signal is HOLD. A domestic-focused pharmaceutical firm that lacks the global scale, regulatory moats, or CDMO capabilities to benefit from the high-conviction healthcare themes.

Key Financial Metrics

Price	$2.28
Market Cap	$557M
P/E (TTM)	21.33
Price/Book	1.90
Return on Equity	8.1%
Return on Invested Capital	8.9%
Debt/Equity	3.68
Gross Margin	64.4%
Operating Margin	11.6%
Revenue Growth	-0.9%
Dividend Yield	2.7%
Free Cash Flow	$872K

Hefei Lifeon Pharmaceutical Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Hefei Lifeon Pharmaceutical Co., Ltd.’s (003020.SZ) StockRank?: MoatMap’s StockRank for Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) is 45/100, with a Hold signal. It is a composite of Quality (69), Value (43), and Momentum (25) factor ranks across MoatMap’s 19,000+ stock universe.
Does Hefei Lifeon Pharmaceutical Co., Ltd. have an economic moat?: Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) has a Quality factor score of 69/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Hefei Lifeon Pharmaceutical Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) is Hold, based on a StockRank of 45/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Hefei Lifeon Pharmaceutical Co., Ltd. in?: Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).